ArticleThe Journal of infection2021
Mucormycosis-A serious threat in the COVID-19 pandemic?
Article in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review on SARS-CoV-2-associated fungal coinfections.Journal of medical virology · 2022Pooled it
- Automated diagnosis of COVID-19 using radiological modalities and Artificial Intelligence functionalities: A retrospective study based on chest HRCT database.Biomedical signal processing and control · 2023Article
- Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19.Environmental science and pollution research international · 2023Review
- Oral Tissue Involvement and Probable Factors in Post-COVID-19 Mucormycosis Patients: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2022Article
- Long-term side effects and lingering symptoms post COVID-19 recovery.Reviews in medical virology · 2022Review
- New insights on mucormycosis and its association with the COVID-19 pandemic.Future science OA · 2022Review
- Evaluating heating, ventilation, and air-conditioning systems toward minimizing the airborne transmission risk of Mucormycosis and COVID-19 infections in built environment.Case studies in thermal engineering · 2021Article
- Mucormycosis - An opportunistic infection in the aged immunocompromised individual: A reason for concern in COVID-19.Maturitas · 2021Article
- Opportunistic mycoses in COVID-19 patients/survivors: Epidemic inside a pandemic.Journal of infection and public health · 2021Review
- COVID-19-associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic's second wave in India.PLoS neglected tropical diseases · 2021Review
- Consecutive Hits of COVID-19 in India: The Mystery of Plummeting Cases and Current Scenario.Archives of Razi Institute · 2021Review
- COVID-19 associated mucormycosis (CAM) in India: a formidable challenge.The British journal of oral & maxillofacial surgery · 2021Article
- COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors.Journal of fungi (Basel, Switzerland) · 2021Article
- Article
- COVID-19 and mucormycosis superinfection: the perfect storm.Infection · 2021Review
- Histatin 5 Metallopeptides and Their Potential againstBiomolecules · 2021Review
- The microbiota-related coinfections in COVID-19 patients: a real challenge.Beni-Suef University journal of basic and applied sciences · 2021Review
- Osteomyelitis of the Jaw Due to Mucormycosis after Coronavirus Disease 2019 Infection - A Prospective Study.Annals of maxillofacial surgeryArticle
- COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs.Therapeutic advances in infectious diseaseArticle
Corrections and comments
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.